From the Research
Ohtuvayre is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients, as approved by the US FDA in June 2024 1. The medication is an inhaled, selective phosphodiesterase (PDE) 3 and PDE4 inhibitor, which suggests its mechanism of action is related to the relaxation of airway smooth muscles and reduction of inflammation in the lungs. Key points to consider for Ohtuvayre patient criteria include:
- The patient must be an adult with a diagnosis of COPD
- The medication is intended for maintenance treatment, implying its use is for long-term management of the disease rather than for acute exacerbations
- Patients should be monitored for potential side effects, although the specific monitoring requirements are not detailed in the provided evidence The evidence supporting the use of Ohtuvayre in COPD patients is based on its approval by regulatory authorities, with the specifics of the clinical trials leading to its approval not detailed in the provided texts 1. It's worth noting that the other provided studies relate to antibiotic treatment durations for various infections and do not pertain to the use of Ohtuvayre in COPD management 2, 3, 4, 5. Therefore, when considering Ohtuvayre for a patient, the primary criterion is the presence of COPD in an adult patient, for whom the medication is intended as a maintenance treatment.